|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
|
US6054299A
(en)
|
1994-04-29 |
2000-04-25 |
Conrad; Charles A. |
Stem-loop cloning vector and method
|
|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
|
JP2002527061A
(ja)
|
1998-10-09 |
2002-08-27 |
インジーン・インコーポレイテッド |
ｓｓＤＮＡの酵素的合成
|
|
MXPA01003643A
(es)
|
1998-10-09 |
2003-07-21 |
Ingene Inc |
Produccion de adnss in vivo.
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7708915B2
(en)
|
2004-05-06 |
2010-05-04 |
Castor Trevor P |
Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
|
|
WO2003092665A2
(en)
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
CA2563533C
(en)
|
2004-04-15 |
2013-10-01 |
Shmuel A. Ben-Sasson |
Compositions capable of facilitating penetration across a biological barrier
|
|
US8192718B1
(en)
|
2005-01-04 |
2012-06-05 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
WO2007086881A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ， インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
|
|
BRPI0710503A2
(pt)
|
2006-04-07 |
2011-08-16 |
Merrion Res Iii Ltd |
uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
|
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
|
WO2008050654A1
(en)
|
2006-10-25 |
2008-05-02 |
Panasonic Corporation |
Refrigeration cycle device and fluid machine used for the same
|
|
CA2689042A1
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
|
EP2436376B1
(en)
|
2007-09-28 |
2014-07-09 |
BIND Therapeutics, Inc. |
Cancer cell targeting using nanoparticles
|
|
JP2011500569A
(ja)
|
2007-10-12 |
2011-01-06 |
マサチューセッツ インスティテュート オブ テクノロジー |
ワクチンナノテクノロジー
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
US8318211B2
(en)
|
2008-06-16 |
2012-11-27 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
|
|
EA020954B1
(ru)
|
2008-06-16 |
2015-03-31 |
Бинд Терапьютикс, Инк. |
Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
|
|
JP2011525180A
(ja)
|
2008-06-16 |
2011-09-15 |
バインド バイオサイエンシズ インコーポレイテッド |
治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
|
|
WO2010005726A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
WO2010021865A1
(en)
|
2008-08-18 |
2010-02-25 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
US20100087337A1
(en)
|
2008-09-10 |
2010-04-08 |
Bind Biosciences, Inc. |
High Throughput Fabrication of Nanoparticles
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
US8563041B2
(en)
|
2008-12-12 |
2013-10-22 |
Bind Therapeutics, Inc. |
Therapeutic particles suitable for parenteral administration and methods of making and using same
|
|
JP2012512175A
(ja)
|
2008-12-15 |
2012-05-31 |
バインド バイオサイエンシズ インコーポレイテッド |
治療薬を徐放するための長時間循環性ナノ粒子
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
KR101728655B1
(ko)
|
2008-12-18 |
2017-04-19 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
|
EP2485770A4
(en)
|
2009-10-08 |
2013-04-10 |
Merck Sharp & Dohme |
Novel cationic lipids with short lipid chains for oligonucleotide delivery
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
DK2509634T3
(en)
|
2009-12-11 |
2019-04-23 |
Pfizer |
Stable formulations for lyophilization of therapeutic particles
|
|
EP2515942B1
(en)
|
2009-12-15 |
2020-02-12 |
Pfizer Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
DE102009058769A1
(de)
|
2009-12-16 |
2011-06-22 |
MagForce Nanotechnologies AG, 10589 |
Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
|
|
EP3494963A1
(en)
|
2009-12-18 |
2019-06-12 |
The University of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
CA3009891C
(en)
|
2009-12-23 |
2020-09-15 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
EP2525781A1
(en)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Novel cationic lipids for oligonucleotide delivery
|
|
US9149432B2
(en)
|
2010-03-19 |
2015-10-06 |
Massachusetts Institute Of Technology |
Lipid vesicle compositions and methods of use
|
|
US20130037977A1
(en)
|
2010-04-08 |
2013-02-14 |
Paul A. Burke |
Preparation of Lipid Nanoparticles
|
|
US20110250264A1
(en)
|
2010-04-09 |
2011-10-13 |
Pacira Pharmaceuticals, Inc. |
Method for formulating large diameter synthetic membrane vesicles
|
|
US20110262491A1
(en)
|
2010-04-12 |
2011-10-27 |
Selecta Biosciences, Inc. |
Emulsions and methods of making nanocarriers
|
|
WO2011143230A1
(en)
|
2010-05-10 |
2011-11-17 |
Alnylam Pharmaceuticals |
Methods and compositions for delivery of active agents
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
DK2575767T3
(en)
|
2010-06-04 |
2017-03-13 |
Sirna Therapeutics Inc |
HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
DE102010032758B4
(de)
|
2010-07-29 |
2012-02-23 |
Fujitsu Technology Solutions Intellectual Property Gmbh |
Computersystem, Verfahren zum Programmieren einer Echtzeituhr und Computerprogrammprodukt
|
|
MX2013002332A
(es)
|
2010-08-31 |
2013-03-18 |
Novartis Ag |
Lipidos apropiados para suministro liposomal del arn que codifica la proteina.
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
SI4043040T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
CA2809858C
(en)
|
2010-09-20 |
2019-11-12 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
US20150056300A1
(en)
|
2010-10-22 |
2015-02-26 |
Bind Therapeutics, Inc. |
Therapeutic nanoparticles with high molecular weight copolymers
|
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
MX366228B
(es)
|
2011-03-25 |
2019-07-03 |
Selecta Biosciences Inc |
Nanoportadores sinteticos de liberacion mediada por osmosis.
|
|
MX374963B
(es)
|
2011-04-29 |
2025-03-06 |
Selecta Biosciences Inc |
Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
|
|
ES2795110T3
(es)
|
2011-06-08 |
2020-11-20 |
Translate Bio Inc |
Lípidos escindibles
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
WO2013059922A1
(en)
|
2011-10-25 |
2013-05-02 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
PE20181541A1
(es)
|
2011-10-27 |
2018-09-26 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
|
|
EP2771043A4
(en)
|
2011-10-28 |
2015-04-29 |
Presage Biosciences Inc |
ACTIVE RELEASE PROCEDURE
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
JP6182457B2
(ja)
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
|
|
WO2013090601A2
(en)
|
2011-12-16 |
2013-06-20 |
Massachusetts Institute Of Technology |
Compact nanoparticles for biological applications
|
|
WO2013105101A1
(en)
|
2012-01-13 |
2013-07-18 |
Department Of Biotechnology |
Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
|
|
EP2804632B1
(en)
|
2012-01-19 |
2019-09-18 |
The Johns Hopkins University |
Nanoparticle formulations with enhanced mucosal penetration
|
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
EP2817287B1
(en)
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
WO2014028487A1
(en)
|
2012-08-13 |
2014-02-20 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
IL239344B2
(en)
|
2012-12-12 |
2024-06-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
BR112015015584A2
(pt)
|
2012-12-27 |
2017-12-12 |
Baruch S Blumberg Inst |
novos agentes antivirais contra infecção por hbv
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US10405937B2
(en)
|
2014-04-09 |
2019-09-10 |
Arbutus Medical Inc. |
Drill cover and chuck mechanism
|
|
US20170044540A1
(en)
*
|
2014-04-22 |
2017-02-16 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
AU2016253972B2
(en)
|
2015-04-27 |
2020-01-02 |
Acuitas Therapeutics Inc. |
Nucleoside-modified RNA for inducing an adaptive immune response
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017117528A1
(en)
|
2015-12-30 |
2017-07-06 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
KR101884278B1
(ko)
*
|
2016-02-15 |
2018-08-01 |
충남대학교 산학협력단 |
Foxp3 및 CD200 수용체 활성화제를 포함하는 발작성 질환 예방 또는 치료용 약학적 조성물
|
|
WO2017181026A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Translate Bio Ma, Inc. |
Selective modulation of foxp3 expression
|
|
CN109563511A
(zh)
|
2016-06-30 |
2019-04-02 |
阿布特斯生物制药公司 |
用于递送信使rna的组合物和方法
|
|
WO2018013525A1
(en)
*
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
EP3497221A4
(en)
*
|
2016-08-10 |
2020-02-05 |
Duke University |
COMPOSITIONS, SYSTEMS AND METHODS FOR PROGRAMMING IMMUNE CELL FUNCTION BY TARGETED GENE REGULATION
|
|
US20190255106A1
(en)
|
2016-09-07 |
2019-08-22 |
Flagship Pioneering Inc. |
Methods and compositions for modulating gene expression
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
CA3040337A1
(en)
|
2016-10-26 |
2018-05-03 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
US20190274968A1
(en)
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
CA3042179A1
(en)
*
|
2016-10-31 |
2018-05-03 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
|
|
AU2017374042C1
(en)
|
2016-12-09 |
2024-07-11 |
Acuitas Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
EP3876999A4
(en)
|
2018-11-09 |
2022-08-31 |
Arbutus Biopharma Corporation |
NEGATIVELY CHARGED PEG-LIPID CONJUGATES
|
|
CA3118559A1
(en)
|
2018-11-09 |
2020-05-14 |
Arbutus Biopharma Corporation |
Lipid nanoparticle formulations
|
|
AU2019376006A1
(en)
|
2018-11-09 |
2021-06-03 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
KR20210105889A
(ko)
|
2018-11-09 |
2021-08-27 |
아뷰터스 바이오파마 코포레이션 |
지질 나노입자 제제
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|